multiple choice questions are available for this chapter on www.wiley.com/go/dangas/cardiology
References
1 1 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. The Lancet 2003; 361:13–20.
2 2 Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in‐hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27:779–88.
3 3 Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST‐segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119–77.
4 4 O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction, A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362–425.
5 5 Knot J, Widimsky P, Wijns William, et al. How to set up an effective national primary angioplasty network: lessons learned from five European countries. EuroIntervention 2009; 5:299–309.
6 6 Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. The Lancet 2011; 377:1409–20.
7 7 Romagnoli E, Biondi‐Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST‐segment elevation acute coronary syndrome: the RIFLE‐STEACS (Radial Versus Femoral Randomized Investigation in ST‐Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol 2012; 60:2481–9.
8 8 Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. The Lancet 2015; 385:2465–76.
9 9 Svilaas Tone, Vlaar Pieter J., van der Horst Iwan C., et al. Thrombus Aspiration during Primary Percutaneous Coronary Intervention. N Engl J Med 2008; 358:557–67.
10 10 Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1‐year follow‐up study. The Lancet 2008; 371:1915–20.
11 11 Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST‐segment elevation myocardial infarction. N Engl J Med 2013; 369:1587–97.
12 12 Lagerqvist B, Fröbert O, Olivecrona GK, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med 2014; 371:1111–20.
13 13 Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015; 372:1389–98.
14 14 Jolly SS, James S, Džavík V, et al. Thrombus Aspiration in ST‐Segment‐Elevation Myocardial Infarction: An Individual Patient Meta‐Analysis: Thrombectomy Trialists Collaboration. Circulation 2017; 135:143–52.
15 15 Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30‐day results from a multicenter randomized study. J Am Coll Cardiol 2006; 48:244–52.
16 16 Kaltoft A, Bøttcher M, Nielsen SS, et al. Routine thrombectomy in percutaneous coronary intervention for acute ST‐segment‐elevation myocardial infarction: a randomized, controlled trial. Circulation 2006; 114:40–7.
17 17 Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol 2010; 56:1298–306.
18 18 Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST‐Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction. J Am Coll Cardiol 2016; 67:1235–50.
19 19 Nordmann AJ, Hengstler P, Harr T, et al.Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta‐analysis of randomized controlled trials. Am J Med 2004; 116:253–62.
20 20 Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957–66.
21 21 Kastrati A, Dibra A, Spaulding C, et al. Meta‐analysis of randomized trials on drug‐eluting stents vs bare‐metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28:2706–13.
22 22 Neumann F‐J, Sousa‐Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40:87–165.
23 23 Sorrentino S, Giustino G, Mehran R, et al. Everolimus‐Eluting Bioresorbable Scaffolds Versus Everolimus‐Eluting Metallic Stents. J Am Coll Cardiol 2017; 69:3055–66.
24 24 Montone RA, Niccoli G, Marco F de, et al. Temporal Trends in Adverse Events After Everolimus‐Eluting Bioresorbable Vascular Scaffold Versus Everolimus‐Eluting Metallic Stent Implantation: A Meta‐Analysis of Randomized Controlled Trials. Circulation 2017; 135:2145–54.
25 25 Byrne RA, Alfonso F, Schneider S, et al. Prospective, randomized trial of bioresorbable scaffolds vs everolimus‐eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR‐Absorb MI) trial. Eur Heart J 2019; 40:167–76.
26 26 Park D‐W, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non‐infarct‐related coronary artery disease among patients with ST‐elevation myocardial infarction. JAMA 2014; 312:2019–27.
27 27 Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007; 28:1709–16.
28 28 van der Schaaf RJ, Timmer JR, Ottervanger JP, et al. Long‐term impact of multivessel disease on cause‐specific mortality after ST elevation myocardial infarction treated with reperfusion therapy. Heart 2006; 92:1760–3.
29 29 Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369:1115–23.
30 30 Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion‐only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 2015; 65:963–72.
31 31 Gershlick AH, Banning AS, Parker E, et al. Long‐Term Follow‐Up of Complete Versus Lesion‐Only Revascularization in STEMI and Multivessel Disease: The CvLPRIT Trial. J Am Coll Cardiol 2019; 74:3083–94.
32 32 Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST‐segment elevation myocardial infarction and multivessel disease (DANAMI‐3—PRIMULTI): an open‐label, randomised controlled trial. The Lancet 2015; 386:665–71.
33 33 Smits PC, Abdel‐Wahab M, Neumann F‐J, et al. Fractional Flow Reserve‐Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med 2017; 376:1234–44.
34 34 Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med 2019; 381:1411–21.
35 35 Pasceri V, Patti G, Pelliccia F, et al. Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta‐Analysis